News for Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Call Transcript March 10, 2025Fennec Pharmaceuticals Inc. misses on earnings expectations.

Revenue Growth: Approximately 40% increase in revenues over the past 12 months.Net Product Sales (Q4 2024): $7.9 million, with a quarterly growth rate of appro

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ETCompany ParticipantsRobert Andrade - CFOJeff Hackman -...

~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~

Discover Fennec Pharmaceuticals' Q4 results with a GAAP EPS of -$0.06 and revenue of $7.93M, marking an 18.6% Y/Y decline.

On March 5, 2025, Rosty Raykov, a Director at Fennec Pharmaceuticals Inc (FENC), sold 10,000 shares of the company. Following this transaction, the insider now

**media[559686]**

On December 31, 2024, Solas Capital Management, LLC (Trades, Portfolio) executed a notable transaction involving Fennec Pharmaceuticals Inc. The firm added 327,

On December 31, 2024, DG Capital Management, LLC (Trades, Portfolio) made a strategic decision to reduce its holdings in Fennec Pharmaceuticals Inc by 407,512 s

**media[534926]**

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patie…

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in P

Fennec (FENC) said its marketing partner, Norgine, has received positive final draft guidance from U.K. regulators for its drug Pedmarqsi. Read more here.

**media[497612]**

~ PEDMARQSI®

**media[496467]**

~ $13 Million Convertible Debt Repayment from Available Cash ~

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (FENC; TSX: FRX), a commercial stage specialty pharmaceutical comp